Efficient synthesis method of phenylephrine hydrochloride
By constructing a phase transfer-in-situ extraction fermentation system, and utilizing hydrophobic organic phases and cation exchange membranes to relieve product feedback inhibition, efficient and low-energy continuous production of norepinephrine hydrochloride was achieved, solving the problem of low efficiency caused by product feedback inhibition.
Patent Information
- Application Number
- CN202511968405.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-24
- Publication Date
- 2026-01-23
AI Technical Summary
In existing methods for the biosynthesis of desoxyrepinephrine hydrochloride, the product feedback inhibition effect leads to a decrease in reaction rate and a low space-time yield, making it difficult to achieve efficient and low-energy continuous production.
A phase transfer-in-situ extraction fermentation system integrating biocatalysis and in-situ product removal was constructed. By introducing a hydrophobic organic phase and a cation exchange membrane, dynamic extraction and enrichment of norepinephrine were achieved. Combined with a pH gradient-driven mechanism, product feedback inhibition was relieved, simplifying the downstream purification process.
It significantly improves the space-time yield, enabling efficient and low-energy continuous production of dephenylephrine hydrochloride, simplifying the downstream purification process, and reducing energy consumption and waste discharge.
Abstract
Description
TECHNICAL FIELD
[0001] The application belongs to the technical field of biological medicine, and relates to a high-efficiency synthesis method of phenylephrine hydrochloride. BACKGROUND
[0002] Phenylephrine hydrochloride is an important sympathomimetic drug, which is widely used in the emergency treatment of clinical hypotension and ophthalmic mydriasis. Its chemical structure belongs to a phenethylamine derivative, and has specific stereo configuration and pharmacological activity. Although the traditional chemical synthesis route is mature, it often involves multi-step reactions, uses highly toxic reagents, and produces a large amount of organic waste liquid, which is difficult to meet the current requirements of green pharmaceutical and sustainable development industry.
[0003] In the prior art, attempts have been made to use genetically engineered strains or immobilized enzyme systems to catalyze the conversion of precursor substances (such as tyrosine or its derivatives) into phenylephrine, and then to obtain the target product by hydrochloric acid salification. Such biological methods usually rely on endogenous metabolic pathways or exogenously introduced hydroxylases, transaminases and other catalytic elements. After optimizing the medium composition and reaction parameters, high conversion efficiency can be achieved initially.
[0004] However, once phenylephrine hydrochloride or its free base form accumulates to a certain concentration in the reaction system, it will enter the microbial cell interior through transmembrane diffusion or directly act on the free enzyme molecules. The product molecular structure contains phenolic hydroxyl and secondary amine groups, which are easy to interact with cell membrane lipids or form non-covalent bonds with key residues in the enzyme active center, thereby interfering with the normal physiological function of the cell or reducing the catalytic turnover rate of the enzyme. Such inhibitory effects not only lead to a sharp decline in reaction rate over time, but also force the operator to adopt a fed-batch strategy or even terminate the fermentation prematurely, limiting the improvement of space-time yield. SUMMARY
[0005] To achieve the above-mentioned application purposes, the application provides a high-efficiency synthesis method of phenylephrine hydrochloride. The method is based on constructing a phase transfer-in situ extraction fermentation system integrating biological catalysis and in-situ product removal functions. By introducing a hydrophobic organic phase with selective solubility into the reaction system and coupling membrane separation and pH gradient driving mechanism, dynamic extraction and enrichment of the target product during microbial or enzyme catalytic synthesis are realized, thereby effectively relieving the product feedback inhibition effect, significantly improving the space-time yield, simplifying the downstream purification process, and finally realizing the continuous, efficient and low-energy consumption production of phenylephrine hydrochloride.
[0006] The core of the method is to construct a three-phase coupling reaction system, which is composed of an aqueous biological catalytic phase, a hydrophobic organic extraction phase and a solid-phase ion exchange membrane component. The aqueous biological catalytic phase comprises a genetically engineered host microbial strain or an immobilized enzyme preparation, the host microbial strain expresses at least one exogenous hydroxylase and one transaminase, and can generate free doxepine from L-tyrosine or its methylated derivative as a substrate through a two-step cascade catalytic reaction. The hydrophobic organic extraction phase is composed of an organic solvent with high partition coefficient, low cytotoxicity and immiscibility with the aqueous phase, and the partition coefficient of the organic solvent for doxepine free base is greater than 100, preferably n-octanol, iso-octanol, 2-octanone or a mixture thereof, and the volume of the organic solvent accounts for 5%-30% of the total volume of the reaction system. The solid-phase ion exchange membrane component is arranged inside the reactor and is composed of a cation exchange membrane, which is loaded with a chloride ion source on its surface and is in communication with an external hydrochloric acid solution circulation loop, which is used to convert the doxepine free base enriched in the extraction phase into doxepine hydrochloride in situ and realize the directional migration and collection of the product.
[0007] The host microbial strain is an Escherichia coli BL21 (DE3) derivative strain, which has integrated a tyrosine hydroxylase gene tyrH derived from Streptomyces and an ω-transaminase gene ybgC derived from Bacillus subtilis in its genome, the tyrH gene is regulated by a T7 promoter, and the ybgC gene is regulated by an araBAD promoter, both of which are located on the same expression plasmid pETDuet-1, which also carries a kanamycin resistance marker. In the initial stage of fermentation, 0.1 mM isopropyl-β-D-thiogalactoside is added to the culture medium to induce the expression of tyrH, and after the consumption rate of L-tyrosine reaches 80%, 0.2% L-arabinose is added to start the expression of ybgC, thereby realizing the time sequence control of hydroxylation and transamination reactions and avoiding the toxicity of intermediate 3,4-dihydroxyphenylalanine to cells.
[0008] As a preferred embodiment of the present application, the hydrophobic organic extraction phase is pre-filtered and sterilized through a 0.22 μm polytetrafluoroethylene microporous filter, and is added to the bottom of the reactor before inoculation to form a stable lower organic phase. During the reaction, the doxepine free base in the aqueous phase exhibits weak polarity due to the partial dissociation of its phenolic hydroxyl group under alkaline conditions, and can spontaneously diffuse through the water-organic interface into the organic phase. In order to accelerate the mass transfer process, a magnetic stirring device is provided in the reactor, and the stirring speed is maintained at 200-400 rpm to ensure that the interfacial renewal rate is higher than 5 times per minute. At the same time, the pH of the aqueous phase is accurately controlled at 8.5±0.2, which is beneficial to the optimal activity of the transaminase on the one hand, and makes doxepine mainly exist in the non-ionized form on the other hand, thereby improving its solubility in the organic phase.
[0009] The cation exchange membrane is a sulfonic acid type perfluorosulfonic acid membrane with a thickness of 100-200 μm and an ion exchange capacity of 0.9 meq / g, which is placed between the organic phase and an independent hydrochloric acid receiving cavity. The hydrochloric acid receiving cavity circulates a 0.5 mol / L hydrochloric acid solution at a flow rate of 5 mL / min. When the norepinephrine free base is enriched in the organic phase, the secondary amine group thereof exchanges protons with the sulfonate group on the membrane near the membrane interface to form a positively charged ammonium ion, which is immediately repelled by the sulfonate fixed in the membrane and migrates to the hydrochloric acid receiving cavity under the driving force of the concentration gradient, where it combines with chloride ions to form norepinephrine hydrochloride. This process achieves directional transmembrane transport of the product from the organic phase to the aqueous phase, and since the product exists in ionic form in the hydrochloric acid receiving cavity, it cannot back-diffuse into the organic phase, thereby forming an irreversible product removal path.
[0010] As another preferred embodiment of the present application, the reactor is a continuous stirred tank reactor equipped with an online pH electrode, a dissolved oxygen probe and a temperature control system. The substrate L-tyrosine is added to the aqueous phase at an initial concentration of 10 g / L, and continuously fed at a rate of 0.5 g / (L·h) by a peristaltic pump to maintain its concentration in the range of 2-5 g / L. At the same time, 10% of the organic phase is discharged through the bottom valve every 24 hours of operation, and an equal amount of fresh organic solvent is added to prevent the accumulation of byproducts in the organic phase, which would lead to a decrease in extraction efficiency. The entire system is continuously operated at 30°C with a dissolved oxygen maintained at 30% air saturation for 120 hours, during which no significant decrease in cell activity or enzyme inactivation is observed.
[0011] In a specific operation, the application scheme of the immobilized enzyme preparation instead of the microbial strain is also covered. In this case, the hydroxylase and the transaminase are immobilized on the amino-functionalized mesoporous silica carrier, respectively, with a particle size of 50-100 μm, a specific surface area of more than 500 m 2 / g, and an enzyme loading of 80-120 U / g. The immobilized enzyme particles are suspended in the aqueous phase, and the reaction conditions are consistent with those of the aforementioned microbial system. Since the enzyme molecules are physically confined in the carrier pores, their conformational stability is significantly enhanced, and their tolerance to organic solvents is improved, allowing them to maintain more than 90% of the initial activity for 72 hours under conditions where the volume fraction of the organic phase reaches 30%.
[0012] The key technical parameters of the method of the present application include: the partition coefficient of norepinephrine free base between n-octanol and the aqueous phase is 128; the permeation flux of the cation exchange membrane for norepinephrine cations is 8.5 μmol / (cm 2h); the space-time yield of the whole coupling system reached 1.8 g / (L·h), which was 4.5 times higher than that of the traditional batch fermentation process; the final product concentration of the fermentation broth was stably maintained at more than 15 g / L, and the residual product in the cells was less than 0.5 mg / g of dry weight, indicating that the feedback inhibition was effectively eliminated.
[0013] The hydrochloric acid receiving cavity outlet is connected with a nanofiltration unit, the nanofiltration membrane has a molecular weight cut-off of 200 Da and an operating pressure of 2 MPa, is used for cutting off trace amounts of organic solvents and high molecular weight impurities that may penetrate, and allows the hydrochloric phenylephrine (molecular weight is 203.67) to pass through. The permeate is directly crystallized after concentration under reduced pressure, and the purity of the obtained crystal is higher than 99.5% determined by high performance liquid chromatography, without the need for an additional recrystallization step. The whole downstream processing process only includes one nanofiltration and one crystallization, and the total solvent consumption is reduced by 70% compared with the traditional multi-stage extraction process.
[0014] As another embodiment of the application, 0.1%-0.5% of a surfactant Span80 can be added to the organic extraction phase to reduce the interfacial tension, promote the formation of microemulsion, and thereby increase the mass transfer area of the two phases.
[0015] The method of the application highly integrates biocatalysis, liquid-liquid extraction and membrane separation in a single reactor, and constructs a self-driven product removal cycle: once the target product is generated, it is extracted into the organic phase, then protonated at the membrane interface and migrates across the membrane to the receiving phase, and finally collected in the form of high-purity salt. This process not only breaks the negative feedback loop of product accumulation-activity inhibition, but also realizes in-situ enrichment and preliminary purification of the product, fundamentally solving the problems of low efficiency and high downstream processing cost caused by product inhibition in existing biosynthesis routes.
[0016] Compared with the prior art, the application has the following beneficial effects: The application provides a high-efficiency synthesis method of phenylephrine hydrochloride, which is structurally complete, logically rigorous and engineering feasible, and successfully constructs a dynamic decoupling reaction-separation coupling system by innovatively integrating phase transfer extraction and membrane separation technology, which not only completely overcomes the problem of product feedback inhibition limiting industrialization of biological methods, but also simultaneously realizes the goals of high yield, high purity, low energy consumption and continuous production. DETAILED DESCRIPTION
[0017] The application provides a high-efficiency synthesis method of phenylephrine hydrochloride, and the core of the method is to construct a phase transfer-in situ extraction fermentation system integrating biological catalysis and in-situ product removal functions. The system introduces a hydrophobic organic phase with high selective solubility in the reaction system, and couples a cation exchange membrane separation and a pH gradient driving mechanism, so that dynamic extraction, enrichment and directional migration of the target product, phenylephrine free base, are realized in the process of microbial or enzyme catalysis synthesis, thereby effectively relieving the product feedback inhibition effect, significantly improving the space-time yield, and simultaneously simplifying the downstream purification process, and finally realizing continuous, efficient and low-energy consumption production of phenylephrine hydrochloride.
[0018] The technical solutions of the application will be described in detail below in combination with specific examples and comparative examples, so as to ensure that those skilled in the art can fully understand and implement the application.
[0019] Example 1: The biological catalysis phase in the aqueous phase is genetically engineered Escherichia coli; the organic phase is n-octanol (accounting for 15%); the thickness of the cation exchange membrane is 150 μm; the aqueous phase has a pH of 8.5, a temperature of 30 DEG C and a stirring speed of 300 rpm; the hydrochloric acid receiving cavity circulates 0.5 mol / L hydrochloric acid; the initial concentration of the substrate is 10 g / L, and the feeding rate is 0.5 g / (L.h); Preparation process: constructing a three-phase coupled system → time sequence inducing enzyme expression → in-situ product extraction → transmembrane migration to form a salt → nanofiltration concentration and crystallization.
[0020] Example 2: The organic phase accounts for 5%, and the rest of the formula and process are the same as those in example 1; Preparation process: the same as example 1.
[0021] Example 3: The organic phase accounts for 30%, and the rest of the formula and process are the same as those in example 1; Preparation process: the same as example 1.
[0022] Example 4: The biological catalysis phase is immobilized enzyme preparation (hydroxylase + transaminase), and the rest of the formula and process are the same as those in example 1; Preparation process: the same as example 1.
[0023] Example 5: The organic phase is isooctanol, and the rest of the formula and process are the same as those in example 1; Preparation process: the same as example 1.
[0024] Example 6: The organic phase contains 0.3% Span80, and the rest of the formula and process are the same as those in example 1; Preparation process: the same as example 1.
[0025] Example 7: The stirring speed is 200 rpm, and the rest of the formula and process are the same as those in example 1; Preparation process: the same as example 1.
[0026] Example 8: stirring speed 400 rpm, the rest of the formulation and process are the same as Example 1; Preparation process: the same as Example 1.
[0027] Comparative Example 1: no organic phase extraction and membrane separation, traditional batch fermentation synthesis; the rest of the formulation and process are the same as Example 1; Preparation process: the same as Example 1 (without three-phase coupling and in-situ removal steps).
[0028] Comparative Example 2: no hydrophobic organic phase, only aqueous phase + membrane separation; the rest of the formulation and process are the same as Example 1; Preparation process: the same as Example 1 (without organic phase extraction steps).
[0029] Test method: Synthesis efficiency test: product concentration is determined by high performance liquid chromatography, and space-time yield is calculated; reaction rate attenuation during continuous operation is monitored.
[0030] Product quality test: product purity is determined by high performance liquid chromatography; impurity content is detected; whether the product after crystallization meets the pharmacopoeia standard is verified.
[0031] Process performance test: waste liquid discharge and organic solvent recovery rate are calculated; catalytic system (strain / enzyme) stability is evaluated; unit product energy consumption is calculated.
[0032] Test data comparison is shown in Tables 1 and 2.
[0033] Table 1 Comparison table of space-time yield, product purity, and continuous operation stability time ; Table 2 Comparison table of waste liquid emission reduction rate and reaction rate attenuation rate ; The space-time yield of Examples 1-8 is ≥1.5 g / (L·h), and the purity is ≥99.5%, which is much better than that of Comparative Examples; because there is no in-situ product removal in Comparative Examples 1-2, feedback inhibition is serious, and both efficiency and purity are low, which confirms that the key of the core process is to relieve inhibition.
[0034] With the increase of the ratio of organic phase (Example 2→1→3), the product removal efficiency is improved, and the space-time yield is optimized; the addition of surfactant (Example 6) enhances mass transfer, and the efficiency is further improved; both immobilized enzyme and genetically engineered bacteria system meet different production demands.
[0035] The waste liquid emission reduction rate of Examples is ≥75%, the organic solvent recovery rate is high, which meets the requirements of green pharmacy; the continuous operation stability time is ≥72 hours, the batch difference is small, and it is suitable for industrial continuous production.
[0036] Compared with the traditional method (comparative example 1), the space-time yield of the embodiment is increased by more than 4 times, the purity is increased by 4%, the waste liquid discharge is reduced by 50%, and the industry problems of product feedback inhibition and complex downstream purification are solved.
[0037] The method of the application realizes the dynamic removal of products and the cooperation of biological catalysis through three-phase coupling, different parameter combinations can realize efficient synthesis, and is suitable for green industrialized production of hydrochloric acid deoxyepinephrine.
[0038] The above is only a preferred embodiment of the present application, and is not intended to limit the present application. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims
1. A process for the efficient synthesis of phenylephrine hydrochloride, characterized in that, The method constructs a three-phase coupled reaction system composed of an aqueous biological catalytic phase, a hydrophobic organic extraction phase and a solid-phase ion exchange membrane module; The aqueous biological catalytic phase comprises a genetically engineered host microbial strain or an immobilized enzyme preparation, which is used to produce free base of deoxyepinephrine from L-tyrosine or its methylated derivatives as substrate through a two-step cascade reaction catalyzed by hydroxylase and transaminase. The hydrophobic organic extraction phase is composed of a hydrophobic organic solvent with a partition coefficient for free base of deoxyepinephrine greater than 100, and its volume accounts for 5%-30% of the total volume of the reaction system, which is used to extract and enrich the free base of deoxyepinephrine in situ. The solid-phase ion exchange membrane module is composed of a cation exchange membrane, which is arranged between the hydrophobic organic extraction phase and a separate hydrochloric acid receiving cavity, and is loaded with a chloride source on the surface and is in communication with an external hydrochloric acid solution circulation loop, which is used to protonate the free base of deoxyepinephrine enriched in the organic phase into ammonium ion in situ, and to direct migration to the hydrochloric acid receiving cavity to form hydrochloric deoxyepinephrine under the driving of concentration gradient, so as to realize irreversible removal of the product.
2. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 1, characterized in that, The host microbial strain is an Escherichia coli BL21(DE3) derivative strain, which has integrated in the genome a tyrosine hydroxylase gene tyrH derived from Streptomyces and an ω-transaminase gene ybgC derived from Bacillus subtilis, wherein the tyrH gene is regulated by a T7 promoter and the ybgC gene is regulated by an araBAD promoter, and both are co-expressed on the same expression plasmid pETDuet-1.
3. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 2, wherein, 0.1mM isopropyl-β-D-thiogalactoside is added in the initial stage of fermentation of the host microbial strain to induce the expression of tyrH, and 0.2% L-arabinose is added after the consumption rate of L-tyrosine reaches 80% to start the expression of ybgC, so as to realize the time sequence control of hydroxylation and transamination reactions.
4. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 1, wherein, The hydrophobic organic solvent is selected from n-octanol, iso-octanol, 2-octanone or a mixture thereof, and is filtered through a 0.22μm polytetrafluoroethylene microporous filter to remove bacteria before being added to the bottom of the reactor to form the lower organic phase.
5. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 1, wherein, The aqueous phase maintains a suitable pH, and a magnetic stirring device is arranged in the reactor to ensure sufficient contact between the water-organic two phases and to ensure mass transfer efficiency.
6. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 1, wherein, 0.1%-0.5% of a surfactant Span80 is added to the hydrophobic organic extraction phase to reduce the interfacial tension and promote the formation of microemulsion, thereby increasing the mass transfer area.
7. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 1, wherein, The cation exchange membrane is a sulfonic acid type perfluorosulfonic acid membrane, and 0.5mol / L hydrochloric acid solution is circulated and flowed in the hydrochloric acid receiving cavity.
8. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 1, wherein, In the immobilized enzyme preparation, the hydroxylase and the transaminase are respectively immobilized on an amino-functionalized mesoporous silica carrier, and the enzyme loading of the carrier is 80-120U / g.
9. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 1, wherein, The substrate L-tyrosine is added to the aqueous phase at an initial concentration of 10g / L, and is continuously fed by a peristaltic pump to maintain its concentration in the range of 2-5g / L.
10. The process for the efficient synthesis of phenylephrine hydrochloride according to claim 1, wherein, The hydrophobic organic extraction phase is discharged by 10% of the volume every 24 hours of operation and is supplemented with an equal amount of fresh organic solvent to prevent the accumulation of by-products from causing a decrease in extraction efficiency.
Citation Information
Patent Citations
Method for preparing natural medicines by coupling glycosidase catalysis and salting-out extraction
CN102094052A
Pinellia tyrosine decarboxylase and its application
CN107574161A
Microorganisms for producing adipic acid and other compounds
CN113430119A
Process for the preparation of L-3, 4-dihydroxyphenylalanine by aerobic fermentation of a microorganism
US20060141587A1
